What is Satellos?
Satellos is dedicated to improving the treatment of Duchenne muscular dystrophy and other muscle diseases by developing small molecule therapeutics that restore the body's ability to regenerate muscle. Their innovative MyoReGenX platform focuses on reactivating the natural repair processes disrupted by the absence of dystrophin. The company targets AAK1, a protein crucial for guiding muscle stem cells in tissue repair. Satellos aims to enhance outcomes for individuals affected by degenerative muscle conditions through their research and therapeutic advancements.
How much funding has Satellos raised?
Satellos has raised a total of $41M across 2 funding rounds:
Corporate Investment
$1M
Other Financing Round
$40M
Corporate Investment (2021): $1M with participation from Parent Project Muscular Dystrophy
Other Financing Round (2024): $40M led by Bloom Burton, LeedCo Financial Group, Canaccord Genuity, and Haywood
Key Investors in Satellos
Bloom Burton
Bloom Burton & Co. specializes in identifying and creating investment opportunities within the healthcare sector, catering to a diverse range of clients from start-ups to established companies. Their services include raising capital, mergers and acquisitions advisory, equity research, and strategic advisory, all aimed at maximizing returns and enhancing company performance.
LeedCo Financial Group
LeedCo is a public accounting firm that offers a range of services including financial reporting, GST reporting, and tax preparation for businesses. Their team of experienced Certified Public Accountants provides personalized assistance in managing bookkeeping through various accounting software.
Canaccord Genuity
Genuity Group is an independent, full-service financial services firm, with operations in two principal segments of the securities industry: wealth management and capital markets. It was established in 1950, and is headquartered in Vancouver, British Columbia.
What's next for Satellos?
With the recent major strategic investment, Satellos is poised to accelerate the development and potential commercialization of its MyoReGenX platform. This significant capital injection, part of its $41M in total funding, will likely fuel further clinical trials, expand research capabilities, and strengthen its position in the competitive landscape of rare disease therapeutics. The company's focus on reactivating natural muscle regeneration processes positions it as a key player in addressing unmet needs in degenerative muscle conditions.
See full Satellos company page
